Results 161 to 170 of about 3,523,765 (264)

How to manage hypersensitivity reactions to enzyme replacement therapy in lysosomal storage diseases? [PDF]

open access: yesOrphanet J Rare Dis
Spataro F   +5 more
europepmc   +1 more source

Altered blood-brain barrier transport of nanotherapeutics in lysosomal storage diseases. [PDF]

open access: yesJ Control Release, 2022
Solomon M   +6 more
europepmc   +1 more source

ROS‐Responsive Nanoparticle Delivery of Dexmedetomidine Protects the Gut Vascular Barrier After Intestinal Ischemia/Reperfusion via the HDAC‐H3K27ac‐TCF4 Axis

open access: yesAdvanced Science, EarlyView.
A low dose of dexmedetomidine, delivered by ROS‐responsive nanoparticles, preferentially accumulates in the ischemic intestine and restores gut vascular barrier integrity after ischemia/reperfusion injury. This nanoparticle‐based strategy prevents bacterial translocation and liver damage without cardiorespiratory side effects, working through HDAC ...
Hu‐Fei Zhang   +10 more
wiley   +1 more source

Secondary accumulation of lyso-platelet activating factors in lysosomal storage diseases. [PDF]

open access: yesMol Genet Metab
Kell P   +10 more
europepmc   +1 more source

Beyond Biomimetics: Pathology‐Informed Engineering Rescues Reconstituted HDL From Inflammatory Dysfunction for Sepsis Immunotherapy

open access: yesAdvanced Science, EarlyView.
A pathology‐informed engineering strategy rescues reconstituted HDL from inflammatory dysfunction in sepsis. By integrating a ceria nanozyme‐celastrol coordination complex, the platform preserves HDL structure and endotoxin handling, sustains hierarchical intracellular delivery, and enhances immunoregulation across pathological models, translating ...
Han Zhou   +12 more
wiley   +1 more source

Lysosomal Storage Diseases—Regulating Neurodegeneration

open access: yesJournal of Experimental Neuroscience, 2016
Rob U. Onyenwoke, Jay E. Brenman
doaj  

Home - About - Disclaimer - Privacy